Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.10 by 32.65 percent. This is a 244.44 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $129.503 million which beat the analyst consensus estimate of $113.055 million by 14.55 percent. This is a 81.48 percent increase over sales of $71.360 million the same period last year.